echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Fosun Pharmaceutical: Chongqing Yaoyou plans to transfer 100% equity of GSK Pharmaceutical (Suzhou) Co., Ltd. to no more than 250 million yuan

    Fosun Pharmaceutical: Chongqing Yaoyou plans to transfer 100% equity of GSK Pharmaceutical (Suzhou) Co., Ltd. to no more than 250 million yuan

    • Last Update: 2019-07-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On the evening of July 8, Fosun Pharmaceutical released a corporate announcement, disclosing that its holding subsidiary Chongqing Yaoyou and GlaxoSmithKline pharmaceuticals (Suzhou) Co., Ltd (hereinafter referred to as "GlaxoSmithKline China") signed an agreement for sale and purchase of the entity registered capital interest in GlaxoSmithKline pharmaceuticals (Suzhou) Co, Ltd (hereinafter referred to as "acquisition agreement"), Chongqing Yaoyou plans to transfer 100% equity of the target company GlaxoSmithKline (Suzhou) Co., Ltd held by GlaxoSmithKline China with no more than RMB 250 million, including drug registration approval of lamivudine (specification: 0.1g) and production license and GMP certificate of its production facilities The price of equity transfer is based on the asset value of the target company, combined with the market scale of its main products, and determined by both parties through negotiation GlaxoSmithKline Pharmaceutical (Suzhou) Co., Ltd was established in September 1997 Its registered address is Suzhou, Jiangsu Province Its legal representative is Esteban Carlos gully Its business scope is to produce and repackage drugs (according to the scope listed in the drug production license); to provide the sales, technology, management services, technology transfer and industrial intellectual property services of the products produced by the enterprise (for the items subject to approval according to law, the business activities can be carried out only with the approval of the relevant departments) As of the announcement date, the registered capital of GSK Pharmaceutical (Suzhou) Co., Ltd is 7.745 million yuan; GSK China holds 100% of its equity According to the audit of Deloitte Touche Tohmatsu certified public accountants LLP, as of December 31, 2018, the total assets of GlaxoSmithKline (Suzhou) Co., Ltd were RMB 1650.75 million, the owner's equity was RMB 1369.91 million, and the total liabilities were RMB 28.84 million; in 2018, GlaxoSmithKline (Suzhou) Co., Ltd realized the main business income of RMB 65, 6.11 million yuan, realizing a net profit of 73.98 million yuan Lamivudine, the core product of GlaxoSmithKline (Suzhou) Co., Ltd (specification: 0.1g), is mainly used in the field of antiviral It has a strong inhibitory effect on hepatitis B virus, and has a strong synergy with the existing product treatment field of Chongqing Yaoyou The acquisition of relevant production facilities will be conducive to further expanding the pharmaceutical manufacturing facilities of Fosun Pharmaceutical in East China and improving the pharmaceutical production capacity After the equity transfer, Chongqing Yaoyou will hold 100% of the target company's equity, and GlaxoSmithKline Pharmaceutical (Suzhou) Co., Ltd will be included in the scope of Fosun Pharmaceutical's consolidated statements The following is the original announcement:
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.